Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. reports developments tied to its online marketplace for human biospecimens, which connects life science researchers with a network of healthcare specimen providers. Company updates cover biospecimen sourcing for research projects, supplier-network responsiveness, direct-to-customer shipping, and marketplace technology used to match customer requests with available inventory.
Recurring news themes include AI-assisted inventory matching, SalesStack marketplace integration, respiratory and other specimen procurement, international sourcing relationships, and capital-structure actions such as the completed reverse stock split of ISPC common stock.
iSpecimen Inc. (Nasdaq: ISPC) announced its marketplace network has exceeded 200 healthcare providers, significantly enhancing access to biospecimens for medical research. This platform connects researchers with healthcare organizations, improving procurement efficiency for crucial samples such as tissues and biofluids. The diverse supplier network ensures a reliable flow of specimens, addressing potential shortages from global disruptions. The company emphasizes compliance and rigorous vetting for its suppliers to maintain high ethical and operational standards.
iSpecimen Inc. (Nasdaq: ISPC) reported a record FY 2021 revenue of $11.1 million, a 36% increase from FY 2020's $8.2 million. The revenue consisted of $8.0 million (72%) from non-COVID-19 related sources and $3.1 million (28%) from COVID-19. The company expanded its supplier network to 200 organizations and customer purchases grew to 415. iSpecimen raised $21 million in a private placement, enhancing its capabilities for biospecimen research. However, net loss increased to $9.0 million from $4.7 million in 2020.
iSpecimen (NASDAQ: ISPC) announced CEO Dr. Christopher Ianelli's participation in the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Dr. Ianelli will present on February 24 at 12:30 p.m. ET. Interested attendees can add the event to their calendars via an iCalendar link. iSpecimen operates an online marketplace for human biospecimens, enabling life scientists to connect with healthcare providers for research needs. For further inquiries or one-on-one meetings, contact KCSA Strategic Communications.
iSpecimen Inc. (NASDAQ: ISPC) will release its fourth quarter and full year financial results for 2021 on February 17, 2022, before market opening. An audio webcast will follow at 8:30 a.m. ET, featuring key executives including CEO Christopher Ianelli. Investors can join the live call at +1-877-425-9470 (U.S.) or +1-201-389-0878 (International). A replay option will be available until March 3, 2022. iSpecimen offers a marketplace for human biospecimens, connecting researchers with healthcare providers.
iSpecimen (Nasdaq: ISPC) announced the addition of a reference lab in New York to enhance its supplier capabilities for COVID-19 research. This lab can sequence hundreds of COVID-19 positive swabs weekly, aiding in the identification of variants like Omicron and Delta. iSpecimen has provided over 15,000 specimens for more than 200 COVID-related projects since the pandemic's onset and has collaborated with the CDC by supplying positive and negative serum samples. This expansion supports researchers' needs for variant identification in the ongoing fight against COVID-19.
iSpecimen Inc. (Nasdaq: ISPC) announced participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Christopher Ianelli will present on-demand starting January 10 at 7:00 a.m. ET. iSpecimen provides an online marketplace connecting life scientists with healthcare providers for biospecimens.
For more details, contact H.C. Wainwright or KCSA Strategic Communications at iSpecimen@kcsa.com.
iSpecimen Inc. (NASDAQ: ISPC) announced a significant expansion of its global supplier network, with 25% of new suppliers located outside the U.S. This growth enhances the iSpecimen Marketplace, which now includes over 200 suppliers. The company aims to meet increasing demands for biospecimens in Europe and Asia-Pacific, supporting various medical research fields. Key benefits include improved access to biospecimens and addressing worldwide research needs. The iSpecimen Marketplace streamlines procurement for life science researchers, tackling the shortage of quality biospecimens.
iSpecimen (Nasdaq: ISPC) announced the expansion of its global biospecimen provider network to support research on neurological disorders, affecting approximately one billion people worldwide. Over the past ten months, it has added over a dozen sample providers, supplying biospecimens such as cerebrospinal fluid and other biofluids. iSpecimen can now provide samples from COVID-19 patients exhibiting neurological symptoms, assisting researchers facing biospecimen shortages. This initiative follows National Epilepsy and Alzheimer’s Awareness Months, aiming to facilitate medical discoveries related to these conditions.
iSpecimen Inc. (Nasdaq: ISPC) has successfully closed a private placement, raising approximately $21 million by selling 1,749,999 shares of common stock and warrants to purchase 1,312,500 shares. Each share was sold at a price of $12.00, accompanied by three-quarters of a warrant, which has an exercise price of $13.00 and a term of five and a half years. The private placement was managed by ThinkEquity. The securities offered will not be registered under the Securities Act, and iSpecimen plans to file a registration statement with the SEC for resale purposes.
iSpecimen (Nasdaq: ISPC) has announced a definitive agreement for a private placement to sell 1,749,999 shares of common stock and warrants, expecting to raise approximately $21.0 million in gross proceeds. Each share is priced at $12.00, accompanied by warrants exercisable at $13.00 per share. The placement is set to close on December 1, 2021, subject to customary conditions. The securities will not be registered under the Securities Act and will require a registration statement for resale. This transaction aims to strengthen the company's liquidity and financial position.